Kidney cancer vaccine made from your own immune cells
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests a personalized kidney cancer vaccine made from your own immune cells. It aims to help your immune system recognize and attack clear cell kidney cancer after surgery, potentially lowering the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have clear cell kidney cancer that has not spread outside the kidney and can be fully removed with surgery
- You are 18 or older and strong enough to do daily activities (performance status 0 or 1)
- If you will receive the vaccine, you must be HLA-A2 positive (a blood test for matching immune system markers)
- You must be able to understand the study and sign consent
- Your blood counts and organ function must meet specific lab thresholds close to the start of treatment
- You must not be pregnant or breastfeeding, and you must use effective birth control during the study and for 4 months after your last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your tumor's specific mutations, given alongside pembrolizumab (an immunotherapy drug). The goal is to see if this combination can help keep advanced kidney cancer from growing.
This trial tests a new immune therapy that uses your own cells to fight kidney cancer. It combines two types of immune cells to help your body attack the tumor, which may slow its growth.
This trial is testing a new type of cell therapy for advanced kidney cancer that has not responded to standard treatments. The therapy takes your own immune cells, modifies them to target a protein called CD70 on the cancer cells, and gives them back to you to help fight the cancer.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests an experimental therapy using special immune cells engineered to target a protein called CD70 on kidney cancer cells. It may help patients whose cancer has returned or spread after previous treatment.
This trial tests a personalized cancer vaccine designed to help your immune system fight any remaining cancer cells after surgery. It is for people with certain solid tumors—like bladder, stomach, melanoma, or lung cancer—that show signs of disease through a blood test.
Hear when a new Carcinoma, Renal Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.